Replimune Group (NASDAQ:REPL) Coverage Initiated by Analysts at Roth Mkm

Roth Mkm began coverage on shares of Replimune Group (NASDAQ:REPL) in a research note released on Tuesday morning, Benzinga reports. The firm issued a buy rating and a $17.00 price target on the stock.

A number of other brokerages have also weighed in on REPL. HC Wainwright boosted their price objective on Replimune Group from $12.00 to $17.00 and gave the stock a buy rating in a research report on Friday, June 7th. Barclays boosted their price objective on Replimune Group from $13.00 to $17.00 and gave the stock an overweight rating in a research report on Friday, June 7th. JPMorgan Chase & Co. reduced their price objective on Replimune Group from $17.00 to $14.00 and set an overweight rating on the stock in a research report on Tuesday, August 13th. Finally, Wedbush restated an outperform rating and set a $16.00 price objective on shares of Replimune Group in a research report on Thursday, June 6th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Replimune Group presently has an average rating of Buy and a consensus price target of $16.20.

Replimune Group Trading Down 2.9 %

Shares of REPL opened at $9.99 on Tuesday. Replimune Group has a 52-week low of $4.92 and a 52-week high of $21.32. The business’s fifty day moving average is $9.58 and its 200-day moving average is $8.12. The company has a debt-to-equity ratio of 0.16, a quick ratio of 13.46 and a current ratio of 13.46. The firm has a market cap of $613.54 million, a price-to-earnings ratio of -3.08 and a beta of 1.25.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.10. Equities analysts anticipate that Replimune Group will post -3.08 EPS for the current fiscal year.

Insider Buying and Selling at Replimune Group

In other Replimune Group news, insider Konstantinos Xynos sold 15,881 shares of the company’s stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $7.50, for a total value of $119,107.50. Following the sale, the insider now owns 117,131 shares in the company, valued at approximately $878,482.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Replimune Group news, insider Konstantinos Xynos sold 15,881 shares of the company’s stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $7.50, for a total value of $119,107.50. Following the sale, the insider now owns 117,131 shares in the company, valued at approximately $878,482.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Emily Luisa Hill sold 8,938 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $10.18, for a total value of $90,988.84. Following the completion of the sale, the chief financial officer now owns 101,057 shares in the company, valued at approximately $1,028,760.26. The disclosure for this sale can be found here. Corporate insiders own 20.60% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

A number of institutional investors have recently made changes to their positions in the stock. Handelsbanken Fonder AB acquired a new position in shares of Replimune Group in the 4th quarter valued at about $101,000. Fisher Asset Management LLC lifted its stake in shares of Replimune Group by 37.7% in the 4th quarter. Fisher Asset Management LLC now owns 77,663 shares of the company’s stock valued at $655,000 after purchasing an additional 21,267 shares during the period. Los Angeles Capital Management LLC acquired a new position in shares of Replimune Group in the 4th quarter valued at about $305,000. E Fund Management Co. Ltd. acquired a new position in shares of Replimune Group in the 4th quarter valued at about $209,000. Finally, BNP Paribas Financial Markets lifted its stake in shares of Replimune Group by 517.9% in the 4th quarter. BNP Paribas Financial Markets now owns 196,251 shares of the company’s stock valued at $1,654,000 after purchasing an additional 164,490 shares during the period. Institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.